Ronac Mamtani

10.9k total citations · 1 hit paper
215 papers, 4.0k citations indexed

About

Ronac Mamtani is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ronac Mamtani has authored 215 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Surgery, 91 papers in Oncology and 52 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ronac Mamtani's work include Bladder and Urothelial Cancer Treatments (58 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Urinary and Genital Oncology Studies (33 papers). Ronac Mamtani is often cited by papers focused on Bladder and Urothelial Cancer Treatments (58 papers), Cancer Immunotherapy and Biomarkers (43 papers) and Urinary and Genital Oncology Studies (33 papers). Ronac Mamtani collaborates with scholars based in United States, Israel and United Kingdom. Ronac Mamtani's co-authors include Kevin Haynes, Ben Boursi, Yu‐Xiao Yang, James D. Lewis, Frank I. Scott, David J. Vaughn, David S. Goldberg, Bruce J. Giantonio, Ido Lurie and Warren B. Bilker and has published in prestigious journals such as JAMA, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Ronac Mamtani

189 papers receiving 4.0k citations

Hit Papers

EV-301 long-term outcomes: 24-month findings from the pha... 2023 2026 2024 2025 2023 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    2023 84 citations Guru Sonpavde, Ronac Mamtani et al. profile →

Peers

Ronac Mamtani
Katja K.H. Aben Netherlands
Tien C. Ko United States
Julio M. Pow‐Sang United States
Mark A. Morgan United States
Jennifer Beebe‐Dimmer United States
Masoud Sotoudeh Iran
James A. Kaye United States
Michel Velten France
Hyun‐Joo Kong South Korea
Konstantinos P. Economopoulos United States
Katja K.H. Aben Netherlands
Ronac Mamtani
Citations per year, relative to Ronac Mamtani Ronac Mamtani (= 1×) peers Katja K.H. Aben

Countries citing papers authored by Ronac Mamtani

Since Specialization
Citations

This map shows the geographic impact of Ronac Mamtani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronac Mamtani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronac Mamtani more than expected).

Fields of papers citing papers by Ronac Mamtani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronac Mamtani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronac Mamtani. The network helps show where Ronac Mamtani may publish in the future.

Co-authorship network of co-authors of Ronac Mamtani

This figure shows the co-authorship network connecting the top 25 collaborators of Ronac Mamtani. A scholar is included among the top collaborators of Ronac Mamtani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronac Mamtani. Ronac Mamtani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chow, Ryan D., Ramy Sedhom, & Ronac Mamtani. (2025). Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer. JAMA Oncology. 12(1). 104–104.
2.
Chen, Kan, et al.. (2025). Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations. Nature Medicine. 31(2). 457–465. 11 indexed citations
3.
4.
Mamtani, Ronac, et al.. (2025). Bayesian re-analysis: Comparing radical cystectomy with trimodality therapy in patients with muscle invasive bladder cancer.. Journal of Clinical Oncology. 43(5_suppl). 737–737.
5.
Mamtani, Ronac, et al.. (2025). Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Urologic Oncology Seminars and Original Investigations. 44(2). 118.e1–118.e5.
6.
Chapin, William J., Wei‐Ting Hwang, Ronac Mamtani, & Mark H. O’Hara. (2024). Low- vs High-Dose 5-FU in Triplet Chemotherapy Plus Bevacizumab for Patients With Colorectal Cancer. JAMA Network Open. 7(7). e2424855–e2424855. 1 indexed citations
7.
Guadamuz, Jenny S., Xiaoliang Wang, Ivy Altomare, et al.. (2024). Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023. JNCI Cancer Spectrum. 8(5).
8.
Brodtkorb, Thor‐Henrik, C Knight, Murat Kurt, et al.. (2024). Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of Medical Economics. 27(1). 543–553. 3 indexed citations
9.
Reibel, Jacob B., Lova Sun, Ravi B. Parikh, et al.. (2024). Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer. JNCI Journal of the National Cancer Institute. 117(6). 1276–1278.
10.
Barsouk, Adam, et al.. (2024). Meta-Analysis of Age, Sex, and Race Disparities in the Era of Contemporary Urothelial Carcinoma Treatment. Cancers. 16(19). 3338–3338. 2 indexed citations
11.
Maitre, Priyamvada, et al.. (2024). Failure Patterns of Bladder Only Hypofractionated Radiation with Gemcitabine in Muscle Invasive Bladder Cancer (MIBC). International Journal of Radiation Oncology*Biology*Physics. 120(2). e573–e573.
12.
Margalit, Ofer, Einat Shacham‐Shmueli, Yu‐Xiao Yang, et al.. (2023). Tumor Differentiation as a Prognostic Marker in Clinically Staged T1bN0 Esophageal Adenocarcinoma. Cancer Investigation. 41(8). 734–738. 1 indexed citations
13.
Jacobs, Linda A., et al.. (2022). Salivary cotinine level and treatment response in muscle invasive bladder cancer: A pilot study. SHILAP Revista de lepidopterología. 4(2). 164–166. 1 indexed citations
14.
Lau‐Min, Kelsey S., Yimei Li, Jennifer R. Eads, et al.. (2021). Adherence to and determinants of guideline‐recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice. Cancer. 127(14). 2562–2570. 1 indexed citations
15.
Sun, Lova, Anh N. Le, Abigail Doucette, et al.. (2020). Rates of COVID-19–Related Outcomes in Cancer Compared With Noncancer Patients. JNCI Cancer Spectrum. 5(1). 27 indexed citations
16.
Zhong, Yichen, Haojie Li, Yang Meng, et al.. (2020). The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. Journal of Medical Economics. 23(9). 967–977. 16 indexed citations
17.
18.
Lewis, James D., Frank I. Scott, Colleen Brensinger, et al.. (2018). Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. The American Journal of Gastroenterology. 113(3). 405–417. 109 indexed citations
19.
Kern, David M., John J. Barron, Bingcao Wu, et al.. (2017). A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data. PubMed. Volume 8. 149–155. 13 indexed citations
20.
Mamtani, Ronac, Kevin Haynes, Ben Boursi, et al.. (2014). Validation of a Coding Algorithm to Identify Bladder Cancer and Distinguish Stage in an Electronic Medical Records Database. Cancer Epidemiology Biomarkers & Prevention. 24(1). 303–307. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katja K.H. Aben Breakdown of academic impact, for papers by Tien C. Ko Breakdown of academic impact, for papers by Julio M. Pow‐Sang Breakdown of academic impact, for papers by Mark A. Morgan Breakdown of academic impact, for papers by Jennifer Beebe‐Dimmer Breakdown of academic impact, for papers by Masoud Sotoudeh Breakdown of academic impact, for papers by James A. Kaye Breakdown of academic impact, for papers by Michel Velten Breakdown of academic impact, for papers by Hyun‐Joo Kong Breakdown of academic impact, for papers by Konstantinos P. Economopoulos
Rankless by CCL
2026